JUN 06, 2019 10:45 AM PDT

Drug Regimen Improves Clinical Outcomes for Kidney Transplant Patients

WRITTEN BY: Nouran Amin

Recent preliminary clinical trial results indicate the immunosuppressive drug belatacept can safely and effectively treat kidney transplant patients without adverse long-term side effects of traditional immunosuppressive regimens. Belatacept was approved by the U.S. Food and Drug Administration in 2011 for the prevention of immune rejection in kidney transplant patients and is the modified form of another drug called abatacept which treats rheumatoid arthritis.

The clinical trial is known as the Belatacept Early Steroid Withdrawal Trial (BEST) represented a significant step forward in enhancing the quality of life for postoperative patients receiving kidney transplantation.

"In the BEST trial, we tried to achieve something that hadn't been done in transplantation: to eliminate the use of corticosteroids very early after surgery and at the same time avoid the toxicities associated with the cornerstone immunosuppressive medications that had been used for four decades," said principal investigator E. Steve Woodle, MD, William A. Altemeier Professor in Research Surgery at the UC College of Medicine and director of Solid Organ Transplantation for UC Health."We wanted to reduce the side effects and toxicities of these medications and make it easier for patients to tolerate their anti-rejection drugs, while achieving rejection rates that are reasonable, this work solved a vexing 40-year-old problem and represents a major step forward in the field of transplantation."

Findings of the two-year study did not utilize the long-term use of prednisone (a corticosteroid) or tacrolimus (a calcineurin inhibitor).

"The primary problem that has prevented elimination of corticosteroids and calcineurin inhibitors to date has been excessive rejection rates," stated Rita Alloway, PharmD, research professor of nephrology at the UC College of Medicine and director of Transplant Clinical Research at UC Health. "The BEST Trial demonstrates that rejection risk with the new belatacept-based regimens was increased somewhat, and the reduced side effects and long-term cardiovascular risk reduction are major potential advantages of these regimens for the future."

Learn more about rejection following transplantation:

The standard care of treatment for patients who receive a kidney transplant is a post-surgery regimen involving corticosteroid and calcineurin inhibitor (CNI) immunosuppressants. These drugs have long been known to help organ transplant patients survive but can result in kidney toxicity or cardiovascular damage.

"This CNI- and steroid-free [immunosuppressive] protocol is a promising step forward in minimizing toxicities and improving renal allograft function," noted the author of the study. "Longer-term observations will need to be continued."

Source: University of Cincinnati

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 18, 2020
Cancer
APR 18, 2020
A New Double Threat Against Skin Cancer
Skin cancer is one of the most common cancers in America.  One of the most aggressive forms of cancer is melanoma, ...
APR 30, 2020
Cancer
APR 30, 2020
A New microRNA for the Cancer Fighting Toolkit
MiRNAs are small snippets of genetic information that regulate gene expression thought to be able to regulate up to 60% ...
MAY 06, 2020
Drug Discovery & Development
MAY 06, 2020
Why Doctors are Repurposing Drugs to Treat COVID-19
Creating a drug from scratch is a lengthy process. Often taking years, given the rate of infection and deadliness of COV ...
MAY 02, 2020
Drug Discovery & Development
MAY 02, 2020
Glioblastoma Treatment Using Schizophrenic Drug Plus Radiation
A therapeutic used for the treatment of schizophrenia could be a gateway for targeting glioblastoma, one of the deadlies ...
MAY 14, 2020
Drug Discovery & Development
MAY 14, 2020
Therapeutic for Gastrointestinal Tumors
The FDA has approved ripretinib (Qinlock) which is the first drug for fourth-line treatment of advanced gastrointestinal ...
MAY 28, 2020
Cancer
MAY 28, 2020
The Oncogenic Hazard of a Potential Alzheimer's Treatment
Breast cancer remains one of the most common cancers around the world. Triple-Negative Breast Cancer (TNBC) is a sub-typ ...
Loading Comments...